(Sharecast News) - Data science and biostatistics company Physiomics said on Thursday that it has secured a "sizeable contract extension award" with an existing large pharmaceutical client.
Physiomics said the project builds upon the contract award announced on 13 June 2024, where its proprietary Virtual Tumour platform has been used to model the client's targeted oncology agents in combination with other modalities so to help inform dose and scheduling decisions.

The AIM-listed group stated the contract extension allows the continuation of this work and further supports the client's expansion into new oncology indications. T

Physiomics added that the project was valued at £143,780 and was projected to be completed over the next six months, with the majority of the contract's value to be recognised in the year ending 30 June 2026.

Chief executive Peter Sargent said: "We are thrilled to have been awarded this sizeable contract extension. The award is testament to the continuation of our deep relationship with this large pharma client and the positive impact we have on their oncology portfolio. It also reflects the power and utility of our Virtual Tumour platform in supporting novel oncology therapies, especially in modelling therapies used in combination with other modalities."

As of 0945 BST, Physiomics shares were down 0.49% at 0.40p.









Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE